> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-149/
- Published: 2017-09-24T12:00:00.000Z
- Updated: 2026-09-14T22:52:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139653

[**Guide on Index of Unapproved New Animal Drugs**](https://www.fdaweb.com/guide-on-index-of-unapproved-new-animal-drugs/)  
*Federal Register* notice: FDA makes available a draft guidance #210 entitled “The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species.” 09/22/2017 

[**PMA Summaries Available for CBER-approved Products**](https://www.fdaweb.com/pma-summaries-available-for-cber-approved-products/)  
*Federal Register* notice: FDA makes available the safety and effectiveness summaries of recent PMAs approved by CBER. 09/22/2017

[**Drug/Biologic User Fees for FY 2018**](https://www.fdaweb.com/drug-biologic-user-fees-for-fy-2018/)  
*Federal Register* notice: FDA announces the rates for prescription drug user fees for fiscal year 2018\. 09/21/2017

[**Biosimilar User Fee Rates for FY 2018**](https://www.fdaweb.com/biosimilar-user-fee-rates-for-fy-2018/)  
*Federal Register* notice: FDA announces rates for biosimilar user fees for fiscal year 2018\. 09/21/2017  
  
[**Draft Guide on Microdose Radiopharmaceutical Diagnostic Drugs**](https://www.fdaweb.com/draft-guide-on-microdose-radiopharmaceutical-diagnostic-drugs/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations.” 09/20/2017

[**PMA Critical to Quality Pilot Program**](https://www.fdaweb.com/pma-critical-to-quality-pilot-program/)  
*Federal Register* notice: FDA announces a “Premarket Approval Application Critical to Quality” pilot program. 09/19/2017

[**Comment Period Extended on Scheduling Changes to 17 Drugs**](https://www.fdaweb.com/comment-period-extended-on-scheduling-changes-to-17-drugs/)  
*Federal Register* notice: FDA extends until 9/20 the comment period for an 8/14 Federal Register notice requesting feedback about abuse potential, actual abus, and impact of scheduling changes on 17 drug substances. 09/19/2017  
  
[**FDA Guide on Device Study Reporting of Age, Race Data**](https://www.fdaweb.com/fda-guide-on-device-study-reporting-of-age-race-data/)  
*Federal Register* notice: FDA makes available a guidance entitled “Evaluation and Reporting of Age, Race, and Ethnicity Data in Medical Device Clinical Studies.” 09/19/2017

[**Vaccines Panel To Discuss 2018 Flu Vaccine**](https://www.fdaweb.com/vaccines-panel-to-discuss-2018-flu-vaccine/)  
*Federal Register* notice: FDA announces a 10/4 Vaccines and Related Biological Products Advisory Committee meeting. 09/18/2017